Eisai starts trials for a second Alzheimer's drug a day after Biogen failure wipes $18B off its value
March 22, 2019 at 06:46 AM EDT
Eisai said it has begun phase 3 clinical trials of Alzheimer's treatment, a day after the Japanese drugmaker and U.S. partner Biogen scrapped trials for its own Alzheimer's drug.
